Search clinical trials for: Lantus (insulin glargine [rDNA origin] injection)

Total 250 results

Merck Sharp & Dohme LLC

Completed

Pharmacodynamic and Pharmacokinetic Variability of a Basal Insulin (0000-168)

Diabetes
Geropharm

Completed

A Study to Compare Pharmacokinetics and Pharmacodynamics of RinGlar® to Lantus® in Type 1 Diabetes Mellitus Patients

Clamp Study

Russian Federation
Sanofi

Completed

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications (SENIOR)

Type 2 Diabetes Mellitus

United States, Australia, Spain, Korea, Republic of, Hungary, Mexico, Italy, Poland, Argentina, Canada, Colombia, France, Germany, Japan, Peru, Romania, Sweden, United Kingdom
Massachusetts General Hospital
Sanofi

Completed

Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon (DAWN)

Type 1 Diabetes | Dawn Phenomenon

United States
Medical University of Vienna

Completed

Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin (LixiBIT)

Type 2 Diabetes Mellitus

Austria
University of Padova

Completed

Endothelial Effects of Basal Insulin: Detemir Versus Glargine

Cardiovascular Disease | Type 2 Diabetes | Endothelial Dysfunction

Italy
Munich Municipal Hospital
Aventis Pharmaceuticals

Unknown

Can Insulin Glargine Improve Myocardial Function in Patients With T2D and Coronary Artery Disease (CAD)

Coronary Artery Disease | Type 2 Diabetes

Germany
Tamra Dukatz
Sanofi

Completed

Perioperative Insulin Glargine Dosing Study

Diabetes | Surgery

United States
Emory University

Completed

Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Sanofi

Terminated

Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction (INTENSIVE)

AMI

Canada, Brazil, United States, Argentina, Mexico
LMC Diabetes & Endocrinology Ltd.

Completed

The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians (VARIATION 2 SA)

Diabetes Mellitus, Type 2

Canada
Emory University
Sanofi; University of Miami

Completed

Basal/Bolus Versus Sliding Scale Insulin In Hospitalized Patients With Type 2 Diabetes

Hyperglycemia | Diabetes

United States
Eli Lilly and Company

Completed

Amendment (g) Unblinded Extension Phase of Somatropin in Patients With Idiopathic Short Stature

Growth Disorder

United States
India Diabetes Research Foundation & Dr. A. Ramachandran...

Completed

A Study on Comparison of Glargine Plus Glulisine With Premixed Insulin in Type 2 Diabetes Patients

Type2 Diabetes

India
Buckinghamshire Healthcare NHS Trust
Novo Nordisk A/S

Unknown

Comparing Long-acting Insulins During Exercise in Type 1 Diabetes

Diabetes Mellitus, Type 1

United Kingdom
University of Aarhus

Completed

Effect of NPH Insulin, Insulin Detemir and Insulin Glargine on GH-IGF-IGFBP Axis

Diabetes Mellitus, Type 1

Denmark
Sanofi

Completed

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine (SORELLA2)

Type 2 Diabetes Mellitus

United States, Argentina, Chile, Colombia, Germany, Hungary, Italy, Korea, Republic of, Romania, Russian Federation, Spain, Turkey
Novo Nordisk A/S

Completed

A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study (SWITCH PRO)

Diabetes Mellitus, Type 2

United States, Slovakia, Canada, South Africa, Puerto Rico, Poland
Sanofi

Completed

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine (SORELLA1)

Type 1 Diabetes Mellitus

Japan, Spain, Germany, United States, France, Hungary, Poland, Russian Federation
Sanofi

Completed

Apidra Children & Adolescents Study

Diabetes Mellitus, Type 1

Russian Federation
Emory University

Completed

Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients (CABG-D/C)

Poor Glycemic Control

United States
Sanofi

Completed

Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Sanofi

Completed

Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy (EDITION AP)

Type 2 Diabetes Mellitus

China, Taiwan, Korea, Republic of
Tehran University of Medical Sciences

Completed

Cost Effectiveness of Glargine Insulin Versus NPH Insulin

Type 2 Diabetes Mellitus

Iran, Islamic Republic of
Inova Health Care Services

Terminated

Comparison of Insulin Therapy in Treating Post-Transplant Diabetes

Diabetes Mellitus

United States
Sanofi

Completed

Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin (Lixilan-L-CN)

Type 2 Diabetes Mellitus

China
Sanofi

Terminated

Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents (LixiLan-D)

Type 2 Diabetes Mellitus

United States
Pfizer

Completed

A Clinical Trial Comparing the Efficacy and Safety of Exubera® and Lantus®

Diabetes Mellitus, Type 2

Germany, Netherlands, Sweden, Poland, Belgium, Finland, France, Norway, Spain, Switzerland
The Cleveland Clinic

Terminated

Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management

Type 1 Diabetes | Type 2 Diabetes | Diabetic Ketoacidosis

United States
Sanofi

Completed

Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs (CHANGING)

Diabetes Mellitus, Type 2

Algeria, Brazil, Israel, Lebanon, Mexico, Morocco, Peru, Saudi Arabia, United Arab Emirates, Venezuela
Sanofi

Completed

Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs (LIXILAN JP-L)

Type 2 Diabetes Mellitus

Japan
Emory University
Sanofi

Completed

Basal Insulin in the Management of Patients With Diabetic Ketoacidosis (DKA)

Diabetic Ketoacidosis

United States
Emory University
Sanofi

Completed

Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery (RABBIT 2-SX)

Type 2 Diabetes | Inpatient Hyperglycemia

United States
Sanofi

Completed

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)

Type 2 Diabetes Mellitus

India
Nordsjaellands Hospital
Odense University Hospital; Zealand University Hospital; Aarhus University Hospital and other collaborators

Completed

Insulin Degludec and Symptomatic Nocturnal Hypoglycaemia (HypoDeg)

Type 1 Diabetes Mellitus | Nocturnal Hypoglycemia | Recurrent Severe Hypoglycaemia

Denmark
Genentech, Inc.

Completed

A Study to Evaluate Nutropin AQ for the Treatment of Growth Restriction in Children With Cystic Fibrosis

Cystic Fibrosis
US Department of Veterans Affairs

Completed

Insulin Secretion in Diabetes Before and After Glycemic Control

Hyperglycemia | Diabetes

United States
Sanofi

Completed

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)

Diabetes Mellitus, Type 2

United States, Canada
Sanofi

Completed

baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus (SUBSTITUTE)

Diabetes Mellitus, Type 1

Tunisia, South Africa, Algeria, Argentina, Brazil, Colombia, Kuwait, Mexico, Saudi Arabia
The University of Texas Health Science Center,...

Completed

Effectiveness of Subcutaneous Glargine On The Time To Closure of The Anion Gap in Patients Presenting to the Emergency Department With Diabetic Keto-acidosis (GT-COG)

Diabetic Ketoacidosis

United States
Sandra Sobel

Completed

Remission Through Early Monitored Insulin Therapy - Duration Month (REMIT-DM)

Type 2 Diabetes Mellitus

United States
Eli Lilly and Company

Terminated

Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lispro Versus Human Regular Insulin (HMH)

Hyperglycemia

United States
Sanofi

Completed

A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

United States, Puerto Rico
Hallym University Medical Center

Completed

Insulin Dose Titration System Using a Short Messaging Service (SMS) Automatically Produced by a Knowledge Matrix

Diabetes Mellitus, Type 2
Chattanooga-Hamilton County Hospital Authority

Terminated

Early Administration of Long-acting Insulin Treatment of Diabetic Ketoacidosis in Pediatric Type 1 Diabetes

Diabetes Mellitus, Type 1 | Diabetic Ketoacidosis

United States
Northumbria University
Newcastle University

Completed

Combined Basal-bolus Insulin and Post-exercise Carbohydrate Feeding Strategy in T1DM

Type 1 Diabetes Mellitus

United Kingdom
Vanderbilt University Medical Center
Sanofi

Completed

Characteristics of Glargine in Type 2 Diabetics

Type 2 Diabetes

United States
Sanofi

Completed

Insulin Glargine, INITIATE Metabolic and Economic Outcomes of Lantus

Diabetes Mellitus

Sweden, Finland, Netherlands, United Kingdom
AstraZeneca
Eli Lilly and Company

Completed

Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Ipsen

Terminated

rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency

Insulin-like Growth Factor-1 Deficiency

United States

3

Subscribe